FORTREA HOLDINGS INC (FTRE)
Health Care · Contract Research Organization (CRO) · NASDAQ
A global contract research organization (CRO) providing full-service and flexible clinical trial management, clinical pharmacology, and drug development solutions to pharmaceutical, biotech, and medical device companies.
What FORTREA HOLDINGS INC does
Fortrea Holdings is a leading global contract research organization (CRO) spun off from Labcorp in June 2023. The company provides biopharmaceutical product and medical device development solutions across clinical pharmacology, clinical development, and consulting services. Operating in approximately 100 countries with roughly 14,300 employees, Fortrea serves pharmaceutical, biotechnology, and medical device customers across more than 20 therapeutic areas, offering flexible engagement models including Full Service, Functional Service Provider (FSP), and Hybrid structures for clinical trials from phase I through IV.
Themes: ["Clinical trial services"]
Fundamentals
- Price$17.67 as of 2026-07-09 close
- Market cap$1.7B as of 2026-07-10
- 1-year return+250.6% as of 2026-07-09 close
- Net margin-16.5% as of 2026-07-10
- Gross margin+18.9% as of 2026-07-10
- ROE-79.1% as of 2026-07-10
- Debt / equity2.00 as of 2026-07-10
- Revenue growth (YoY)+0.9% as of 2026-07-10
- Revenue CAGR (3y)-1.4% SEC XBRL
- Beta2.03 as of 2026-07-10
Key risks (from latest filing)
["Significant accumulated deficit ($1.4 billion as of Q1 2026) and negative net margins (-16.5%), indicating persistent unprofitability post-separation and integration challenges."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.